Table 1

Baseline Characteristics

All Patients (N = 163)Nonsevere MR (n = 113, 69%)Severe MR (n = 50, 31%)p Value
Female39 (24)22 (20)17 (34)0.045
Age, yrs62 ± 1464 ± 1259 ± 170.039
Weight, kg80 ± 1683 ± 1675 ± 150.01
Length, cm173 ± 9173 ± 9172 ± 100.25
Risk factors
 AHT72 (44)52 (46)20 (40)0.45
 Diabetes34 (21)26 (23)8 (16)0.31
 Renal failure24 (15)17 (15)7 (14)0.84
 Active smoking30 (18)21 (19)9 (18)0.92
Heart failure
 Ischemic etiology83 (51)55 (49)28 (56)0.38
 Prior hospitalization78 (48)52 (46)26 (52)0.51
 LVEF, %29 ± 830 ± 727 ± 80.012
NYHA functional class >230 (18)18 (16)12 (24)0.22
Diastolic dysfunction >243 (30)25 (25)18 (42)0.037
Electrophysiology
 Atrial fibrillation20 (12)15 (13)5 (10)0.55
 QRS duration, ms130 ± 31130 ± 31131 ± 310.59
 LBBB56 (34)39 (35)17 (34)0.95
 Prior CRT24 (15)17 (15)7 (14)0.90
 Prior ICD79 (48)55 (49)24 (48)0.93
MR grade 1/2/3/4, (%)39/31/27/356/44/./.././90 /10<0.0001
Medication
 ACEI/ARB153 (94)106 (94)47 (94)0.96
  optimal dose, %5864450.004
 Beta blocker148 (91)101 (89)47 (94)0.34
  optimal dose, %5558490.12
 Loop diuretic agent129 (79)86 (76)43 (86)0.15
 Aldosterone antagonist71 (43)45 (40)26 (52)0.15
  optimal dose, %4747460.7
Left cardiac dimensions (echocardiogram, n = 128)
 LVEDVI, ml/m295 ± 3590 ± 32107 ± 420.01
 LVESVI, ml/m268 ± 3363 ± 2979 ± 390.01
 LAVI, ml/m248 ± 2645 ± 2359 ± 300.007

Values are n (%) or mean ± SD.

ACEI = angiotensin-converting enzyme inhibitor; AHT = arterial hypertension; ARB = angiotensin receptor blocker; CRT = cardiac resynchronization therapy; ICD = implantable cardioverter defibrillator; LAVI = left atrium volume index; LBBB = left bundle branch block; LVEDVI = left ventricular end-diastolic volume index; LVEF = left ventricular ejection fraction; LVESVI = left ventricular end-systolic volume index; MR = mitral regurgitation; NYHA = New York Heart Association.